In Talks With GlaxoSmithKline, Pfizer & Novartis
Mohit Bhalla ET NOW

WOCKHARDT, a troubled drugmaker with huge debts, is in talks with GlaxoSmithKline, Pfizer and Novartis to sign a deal that would give marketing and research rights of its diabetes drugs under development to one of the global companies, two persons familiar with the development said.